The global market for enzyme inhibitors was valued at $104.4 billion in 2010 and reached nearly $104.6 billion in 2011. This market is expected to rise at a compound annual growth rate (CAGR) of 4% and reach nearly $127.4 billion by 2016.
The U.S. market for enzyme inhibitors reached $46.8 billion in 2010 and came down to $44.9 billion in 2011. The market is expected to reach $47.4 billion by 2016, a CAGR of 1.1%.
The kinase inhibitors market reached $10.8 billion in 2010 and came down to $10.4 billion in 2011. The market is expected to reach $11.6 billion by 2016, a CAGR of 2.2%.
GLOBAL REVENUE OF ENZYME INHIBITORS MARKET, 2009-2016
Source: BCC Research
The overall goal of this study is to provide a comprehensive understanding of the current and future characteristics of the global market for enzyme inhibitors.
This report explores present and future strategies within the market for enzyme inhibitors, which includes proton pump inhibitors (PPIs), protease inhibitors, reverse transcriptase inhibitors, kinase inhibitors, statins, aromatase inhibitors, phosphodiesterase type 5 (PDE5) inhibitors, neuraminidase inhibitors, and angiotensin-converting enzyme (ACE) inhibitors. The improvements in the market and the setbacks and needs of the market are discussed in this report. The comparisons, usage, and advantages and disadvantages of different types of enzyme inhibitors are also discussed in this report.
A detailed analysis of the enzyme inhibitors industry structure has been conducted. Revenues are broken down by region. Sales figures are estimated for the five-year forecast period of this report, from 2011 to 2016.
Applications for enzyme inhibitors are also discussed in the report, with emphasis on the usage of the inhibitors in therapeutic categories and various disease sectors. The report also covers significant patents and their allotments in each category.
Extensive research in the field of enzyme inhibitors has revealed their target-specific functionality in being able to provide therapeutic treatments for various chronic diseases. Modern industries have now begun to explore the advantages of enzyme inhibitors in their productions and processes. This has led to steady market growth for enzyme inhibitors.
Research and development (R&D) spending, along with increasing competition, patent expirations and new technologies, is directing this to a new level. Although, due to patent expirations, the overall revenue for the market has decreased slightly from 2009 to 2011, new advancements, new product launches and the changing lifestyle will cause the market to grow in the foreseeable future. This study looks at almost all the systems affected by these factors.
Acquisition strategies and collaborations by companies are also covered in this report. This study also discusses the strengths and weaknesses of each type/technology in light of the new technologies, growing competition and changing customer needs.
This report provides invaluable information to manufacturers and users of PPIs, protease inhibitors, reverse transcriptase inhibitors, kinase inhibitors, statins, aromatase inhibitors, PDE5 inhibitors, neuraminidase inhibitors, and ACE inhibitors. Pharmaceutical and biotechnology companies, research institutes, and physicians will find this study to be of interest.
The scope of this study encompasses enzyme inhibitors in the pharmaceutical and biotechnology industry. BCC Research analyzes each market and its applications, regulatory environment, technology involved, market projections and market share. Technological issues include the latest trends and developments. Emerging markets for enzyme inhibitors include countries such as India, China, Japan, Korea, Taiwan, Canada, Africa, Australia and New Zealand.
The study has been carried out by a team of professionals in the biotechnology industry. The project manager for this project is Shalini S. Dewan, who holds a master's degree in pharmaceutical chemistry and has more than 14 years of industry experience. Among the research topics she has covered are studies on compounds of potential pharmaceutical interest from ibuprofen and 2-naphthyl acetic acid. Dewan was awarded a Gold Medal by the prime minister of India for her work and has worked with top companies in India and in the U.S.
The lead consultant for this project is Dr. Kapil A. Setia, who has a doctorate in life sciences. She has a number of research publications in her credit, including her thesis on “Studies on Phenotypic Variation, Clonal Propagation and Phyto-chemistry of Tinospora cordifolia (Willd.),” which was given an award of excellence.